However, for HR+/HER2− advanced breast cancer patients who progress under CDK4/6 inhibitor and endocrine therapy, there is no standard treatment recommended at the category 1 level in international guidelines, unless there is a positive mutation analysis result. The gene discussed is CDK4; the disease is breast carcinoma.